Precision Management of Late Endocrine Effects in Cancer Survivors
Precision Management of Late Endocrine Effects in Cancer Survivors
Join us for a discussion of the diagnosis and clinical management of late endocrine effects in pediatric and adult cancer survivors. Hear expert perspectives on:
- Common root causes of late endocrine effects due to cancer treatment in survivors of childhood cancer and the importance of lifelong monitoring for their development
- Strategies to address barriers to growth hormone deficiency treatment adherence
- Help understand the challenges of obesity and diabetes mellitus in cancer survivors
This course is a virtual live CME-certified Ancillary Symposium developed in collaboration with our partner - Clinical Care Options (CCO) to be presented at ENDO 2021. This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc. This ancillary symposium is developed through the Endocrine Society’s Special Programs Committee (SPC).
PLEASE REGISTER THEN CLICK "START" TO:
DOWNLOAD PRESENTATION SLIDES
PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION
Click the button(s) below to open the related ClinicalThought commentaries:
Upon successful completion these educational sessions, participants should be better able to:
- Summarize the common root causes of late endocrine effects due to cancer treatment in survivors of childhood cancer and the importance of lifelong monitoring for their development
- Review hypothalamic pituitary disorders in childhood cancer survivors
- Apply practical strategies to diagnosing thyroid disease in pediatric cancer patients and survivors
- Discuss the challenges of obesity and diabetes mellitus in cancer survivors
5:30 – 5:35 PM | Introduction, Pre-Test Polling | Wassim Chemaitilly, MD
5:35 – 5:55 PM | Hypothalamic – Pituitary Axis Dysfunction: Focus on Growth Hormone Deficiency | Laurie E. Cohen, MD
5:55 – 6:15 PM | Thyroid Dysfunction – Primary and Central | Steven G. Waguespack, MD
6:15 – 6:40 PM | Metabolic: Focus on Obesity, Diabetes Mellitus | Danielle N. Friedman, MD, MS
6:40 – 7:00 PM | Closing Remarks, Post-Test Polling, Q&A Session | All Faculty
Wassim Chemaitilly, MD - Program Chair
Associate Member, St. Jude Faculty
Director, Endocrinology Division
St. Jude Children’s Research Hospital
Laurie E. Cohen, MD
Director of the Neuroendocrinology Program
Director of the Growth Program
Director of Clinical Innovation and Digital Health, Division of Endocrinology
Boston Children’s Hospital
Danielle N. Friedman, MD, MS
Pediatric Long-Term Follow-Up Program
Department of Pediatrics
Memorial Sloan Kettering Cancer Center
New York, NY
Steven G. Waguespack, MD
Professor of Internal Medicine and Pediatrics
University of Texas MD Anderson Cancer Center
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Laurie E. Cohen, MD: Research Investigator, Pfizer, Inc.; Speaker, Novo Nordisk; Other, Sandoz
Danielle N. Friedman, MD, MS: Advisory Board Member, Fennec
The following faculty reported no relevant financial relationships during the content development process for this activity: Wassim Chemaitilly, MD; Steven G. Waguespack, MD
The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Beret Anne Casey, MD
The following SPC Committee members reported financial relationships:
- Andjela T. Drincic, MD: Advisory Board Member, Corcept
- Sergio Fazio, MD, PhD: Consultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
- Angela M. Leung, MD: Speaker, Medical Education Resources, MCE Conferences, ATA Board Member
- Amy Rothberg, MD: Spouse, consultant of Merck
- Katherine Araque, MD: Speaker, Novo Nordisk; Advisory Board, Corcept
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The following SPC members reported no relevant financial relationships:
Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD
The staff involved in the development of this CME activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
Use of professional judgment:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
Drugs and dosages:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Novo Nordisk, Inc.
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
AMA PRA Category 1 Credit
The Endocrine Society designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For questions about content or obtaining CME credit, please contact the Endocrine Society at education.endocrine.org/contact.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The Endocrine Society and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
For questions about obtaining Nursing credit, please contact Sophia Kelley at firstname.lastname@example.org.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-21-017-L01-P.
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
For questions about obtaining Pharmacy credit, please contact Sophia Kelley at email@example.com.